title: Atypical infectious mononucleosis in a patient receiving tumor necrosis factor alpha inhibitory treatment.
abstract: The objective is to report a case of atypical acute infectious mononucleosis in a juvenile ankylosing spondylitis patient who was treated with infliximab. A 20-year-old man was hospitalized for the evaluation of lymphadenopathy and systemic symptoms. His symptoms developed at the eighth week of the infliximab treatment and he required hospitalization. Lymph node biopsy was performed and he was diagnosed as atypical infectious mononucleosis (absence of fever, pharyngitis, lymphocytosis and negative atypical lymphocytosis on blood smear). Infections have become major concerns in patients treated with TNF-blocking agents. In theoretical base, it is not surprising as TNF-alpha has a crucial role in the body's defense against both bacterial and viral invasion. Blocking the action of TNF may also change the course of the disease and could lead to a delay in the diagnosis. TNF-alpha-blocking treatment may mask the typical symptoms of infectious mononucleosis and atypical cases should be included in the differential diagnosis of lymphadenopathy in patients receiving anti-TNF-alpha agents.
authors.affiliation: Division of Rheumatology, Department of Internal Medicine, Dokuz Eylul University School of Medicine, Izmir, Turkey. Ismail.sari@deu.edu.tr
authors.forename: Ismail
authors.initials: I
authors.lastname: Sari
authors.forename: Merih
authors.initials: M
authors.lastname: Birlik
authors.forename: Servet
authors.initials: S
authors.lastname: Akar
authors.forename: Fatos
authors.initials: F
authors.lastname: Onen
authors.forename: Aydanur
authors.initials: A
authors.lastname: Kargi
authors.forename: Nurullah
authors.initials: N
authors.lastname: Akkoc
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000009:adverse effects; D003951:Diagnostic Errors; D042241:Early Diagnosis; D006801:Humans; D007108:Immune Tolerance / Q000187:drug effects / Q000276:immunology; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D007244:Infectious Mononucleosis / Q000139:chemically induced* / Q000276:immunology* / Q000821:virology; D000069285:Infliximab; D008206:Lymphatic Diseases / Q000139:chemically induced / Q000276:immunology / Q000821:virology; D008297:Male; D009894:Opportunistic Infections / Q000139:chemically induced / Q000276:immunology / Q000821:virology; D018570:Risk Assessment; D013167:Spondylitis, Ankylosing / Q000188:drug therapy* / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000172:deficiency; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab